Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents

DS Albers and PK Sonsalla

Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, USA.

Neurotoxic doses of methamphetamine (METH) can cause hyperthermia in experimental animals. Damage sustained to dopaminergic nerve terminals by this stimulant can be reduced by environmental cooling or by pharmacological manipulation which attenuates the hyperthermia. Many pharmacological agents with very diverse actions protect against METH- induced neuropathology. Several of these compounds, as well as drugs which do not protect, were investigated to determine if there was a relationship between protection and METH-induced hyperthermia. Mice received METH with or without concurrent administration of other drugs and core (i.e., colonic) temperature was monitored during treatment. The animals were sacrificed > or = 5 days later and neostriatal tyrosine hydroxylase activity and dopamine were measured. Core temperature was significantly elevated (> or = 2 degrees C) in mice treated with doses of METH which produced > or = 90% losses in striatal dopamine but not in mice less severally affected (only 50% loss of dopamine). Concurrent treatment of mice with METH and pharmacological agents which protected partially or completely from METH-induced toxicity also prevented the hyperthermic response (i.e., dopamine receptor antagonists, fenfluramine, dizocilpine, alpha-methyl-p- tyrosine, phenytoin, aminooxyacetic acid and propranol). These findings are consistent with the hypothesis that the hyperthermia produced by METH contributes to its neuropathology. However, studies with reserpine, a compound which dramatically lowers core temperature, demonstrated that hyperthermia per se is not a requirement for METH- induced neurotoxicity. Although core temperature was elevated in reserpinized mice treated with METH as compared with reserpinized control mice, their temperatures remained significantly lower than in nonreserpinized control mice. However, the hypothermic state produced in the reserpinized mice did not provide protection from METH-induced toxicity. These data demonstrate that hyperthermia per se contributes to but is not solely responsible for the METH-induced neuropathology.

Volume 275, Issue 3, pp. 1104-1114, 12/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				G. C. Hadlock, A. J. Baucum II, J. L. King, K. A. Horner, G. A. Cook, J. W. Gibb, D. G. Wilkins, G. R. Hanson, and A. E. Fleckenstein Mechanisms Underlying Methamphetamine-Induced Dopamine Transporter Complex Formation J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 169 - 174. [Abstract] [Full Text] [PDF]

				J. Yuan, G. Hatzidimitriou, P. Suthar, M. Mueller, U. McCann, and G. Ricaurte Relationship between Temperature, Dopaminergic Neurotoxicity, and Plasma Drug Concentrations in Methamphetamine-Treated Squirrel Monkeys J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1210 - 1218. [Abstract] [Full Text] [PDF]

				D. J. Eyerman and B. K. Yamamoto Lobeline Attenuates Methamphetamine-Induced Changes in Vesicular Monoamine Transporter 2 Immunoreactivity and Monoamine Depletions in the Striatum J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 160 - 169. [Abstract] [Full Text] [PDF]

				A. Iwashita, K. Mihara, S. Yamazaki, S. Matsuura, J. Ishida, H. Yamamoto, K. Hattori, N. Matsuoka, and S. Mutoh A New Poly(ADP-Ribose) Polymerase Inhibitor, FR261529 [2-(4-Chlorophenyl)-5-quinoxalinecarboxamide], Ameliorates Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1114 - 1124. [Abstract] [Full Text] [PDF]

				K. L. Johnson-Davis, J. G. Truong, A. E. Fleckenstein, and D. G. Wilkins Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 578 - 586. [Abstract] [Full Text] [PDF]

				A. J. Baucum II, K. S. Rau, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methamphetamine Increases Dopamine Transporter Higher Molecular Weight Complex Formation via a Dopamine- and Hyperthermia-Associated Mechanism J. Neurosci., March 31, 2004; 24(13): 3436 - 3443. [Abstract] [Full Text] [PDF]

				A. Nakajima, K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, T. Mamiya, J. He, A. Nitta, M. Mizuno, M. H. Tran, et al. Role of Tumor Necrosis Factor-{alpha} in Methamphetamine-Induced Drug Dependence and Neurotoxicity J. Neurosci., March 3, 2004; 24(9): 2212 - 2225. [Abstract] [Full Text] [PDF]

				J. L. CADET, S. JAYANTHI, and X. DENG Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis FASEB J, October 1, 2003; 17(13): 1775 - 1788. [Abstract] [Full Text] [PDF]

				P. L. Brown, R. A. Wise, and E. A. Kiyatkin Brain Hyperthermia Is Induced by Methamphetamine and Exacerbated by Social Interaction J. Neurosci., May 1, 2003; 23(9): 3924 - 3929. [Abstract] [Full Text] [PDF]

				J. Yuan, B. J. Cord, U. D. McCann, B. T. Callahan, and G. A. Ricaurte Effect of Glucoprivation on Serotonin Neurotoxicity Induced by Substituted Amphetamines J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 831 - 839. [Abstract] [Full Text] [PDF]

				J. M. Brown, E. L. Riddle, V. Sandoval, R. K. Weston, J. E. Hanson, M. J. Crosby, Y. V. Ugarte, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein A Single Methamphetamine Administration Rapidly Decreases Vesicular Dopamine Uptake J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 497 - 501. [Abstract] [Full Text] [PDF]

				G. Battaglia, F. Fornai, C. L. Busceti, G. Aloisi, F. Cerrito, A. De Blasi, D. Melchiorri, and F. Nicoletti Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity J. Neurosci., March 15, 2002; 22(6): 2135 - 2141. [Abstract] [Full Text] [PDF]

				T. Xie, L. Tong, T. Barrett, J. Yuan, G. Hatzidimitriou, U. D. McCann, K. G. Becker, D. M. Donovan, and G. A. Ricaurte Changes in Gene Expression Linked to Methamphetamine-Induced Dopaminergic Neurotoxicity J. Neurosci., January 1, 2002; 22(1): 274 - 283. [Abstract] [Full Text] [PDF]

				A. Heller, N. Bubula, R. Lew, B. Heller, and L. Won Gender-Dependent Enhanced Adult Neurotoxic Response to Methamphetamine following Fetal Exposure to the Drug J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 769 - 779. [Abstract] [Full Text] [PDF]

				T. Xie, U. D. McCann, S. Kim, J. Yuan, and G. A. Ricaurte Effect of Temperature on Dopamine Transporter Function and Intracellular Accumulation of Methamphetamine: Implications for Methamphetamine-Induced Dopaminergic Neurotoxicity J. Neurosci., October 15, 2000; 20(20): 7838 - 7845. [Abstract] [Full Text] [PDF]

				S. Kim, R. Westphalen, B. Callahan, G. Hatzidimitriou, J. Yuan, and G. A. Ricaurte Toward Development of an In Vitro Model of Methamphetamine-Induced Dopamine Nerve Terminal Toxicity J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 625 - 633. [Abstract] [Full Text]

				K. B. Burrows, W. L. Nixdorf, and B. K. Yamamoto Central Administration of Methamphetamine Synergizes with Metabolic Inhibition to Deplete Striatal Monoamines J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 853 - 860. [Abstract] [Full Text]

				D. M. Kuhn, C. W. Aretha, and T. J. Geddes Peroxynitrite Inactivation of Tyrosine Hydroxylase: Mediation by Sulfhydryl Oxidation, not Tyrosine Nitration J. Neurosci., December 1, 1999; 19(23): 10289 - 10294. [Abstract] [Full Text] [PDF]

				X. Deng, B. Ladenheim, L.-I Tsao, and J. L. Cadet Null Mutation of c-fos Causes Exacerbation of Methamphetamine-Induced Neurotoxicity J. Neurosci., November 15, 1999; 19(22): 10107 - 10115. [Abstract] [Full Text] [PDF]

				F. Fumagalli, R. R. Gainetdinov, Y.-M. Wang, K. J. Valenzano, G. W. Miller, and M. G. Caron Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice J. Neurosci., April 1, 1999; 19(7): 2424 - 2431. [Abstract] [Full Text] [PDF]

				M. J. LaVoie and T. G. Hastings Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine J. Neurosci., February 15, 1999; 19(4): 1484 - 1491. [Abstract] [Full Text] [PDF]

				L.-I Tsao, B. Ladenheim, A. M. Andrews, C. C. Chiueh, J. L. Cadet, and T.-P. Su Delta Opioid Peptide [D-Ala2,D-leu5]Enkephalin Blocks the Long-term Loss of Dopamine Transporters Induced by Multiple Administrations of Methamphetamine: Involvement of Opioid Receptors and Reactive Oxygen Species J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 322 - 331. [Abstract] [Full Text]

				F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, and M. G. Caron Role of Dopamine Transporter in Methamphetamine-Induced Neurotoxicity: Evidence from Mice Lacking the Transporter J. Neurosci., July 1, 1998; 18(13): 4861 - 4869. [Abstract] [Full Text] [PDF]

				J. W. Gibb, L. Bush, and G. R. Hanson Exacerbation of Methamphetamine-Induced Neurochemical Deficits by Melatonin J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 630 - 635. [Abstract] [Full Text]

				A. E. Fleckenstein, D. G. Wilkins, J. W. Gibb, and G. R. Hanson Interaction Between Hyperthermia and Oxygen Radical Formation in the 5-Hydroxytryptaminergic Response to a Single Methamphetamine Administration J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 281 - 285. [Abstract] [Full Text]

				T. Taraska and K. T. Finnegan Nitric Oxide and the Neurotoxic Effects of Methamphetamine and 3,4-Methylenedioxymethamphetamine J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 941 - 947. [Abstract] [Full Text]